Recorded Presentation from the NCCN Pharmacy Updates: Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer
The biomarker-driven treatment of non-small cell lung cancer is evolving rapidly and pharmacists should be aware of new data, therapies, and treatment recommendations in order to support the multidisciplinary health care team and provide optimal patient care.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
The Importance of Re-Vaccination After Cellular Therapy
Cellular therapies are associated with an increased infection risk, and vaccination in these survivors plays a critical role in lowering that risk. Clinicians need to be educated on the importance of vaccination in these survivors as well as the details of dosing and timing of vaccines to best protect this vulnerable population from vaccine-preventable diseases.
Category
  • Hematologic Malignancies
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Treatment Decisions in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The use of targeted therapies as a preferred treatment approach for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly transformed the treatment landscape of relapsed/refractory disease. The benefit/risk of continuous vs.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing Treatment for Relapsed/Refractory Mantle Cell Lymphoma
The selection of optimal second-line therapy for mantle cell lymphoma (MCL) depends on the age and fitness of the patients as well as the eligibility for transplant or CAR T-cell therapy. In the absence of standard management, patients with relapsed/refractory MCL should be referred for participation in prospective clinical trials investigating novel treatment regimens.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Debate: Transplant vs. CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Educating clinicians about the recent clinical advances and the benefits/risks associated with the use of transplant and CAR T-cell therapy can help them to make informed clinical decisions for individual patients.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
ECHELON-1: Do Updated Results Change the First-Line Treatment of Stage III-IV Classical Hodgkin Lymphoma?
An awareness of the updated safety and efficacy results from the ECHELON-1 trial will help clinicians determine how to optimally incorporate BV-AVD regimen as fist-line therapy in appropriately selected patients with stage III-IV classical Hodgkin lymphoma.
Category
  • Hodgkin Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Familial/Genetic Leukemia Syndromes: Impact on Patient Care
Clinicians need education regarding which patients with leukemia are candidates for genetic counseling and testing and how the management of patients with known germline mutations is affected. This knowledge will help clinicians provide these patients with optimal care.
Category
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Chronic Myelogenous Leukemia
  • Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Hematopoietic Growth Factors: Use of Thrombopoietin Receptor Agonists in Patients with Cancer
Since there is currently no FDA-approved treatment for CIT, clinicians must make decisions on the appropriate incorporation of thrombopoietin receptor agonists (TPO-RAs) into clinical practice. Increased education and awareness of the available treatment options, including TPO-RA, will help to ensure the acceptance and use of these agents in supportive oncology care for patients with CIT.
Category
  • Myeloid Growth Factors
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Management of Chronic Phase Chronic Myeloid Leukemia with Resistance to Multiple TKIs
In the majority of patients responding to TKI therapy, chronic myeloid leukemia (CML) is now managed like a chronic disease. However, it poses significant challenges to the clinicians in terms of selection of alternate TKI therapy in patients with inadequate initial response to initial TKI therapy. Informing clinicians about the recent FDA approvals would assist in the incorporation of new treatment options into their routine clinical practice to improve patient outcomes.
Category
  • Chronic Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Managing Cardiovascular Events in Multiple Myeloma
With careful risk assessment, monitoring, and prophylactic treatment, the cardiovascular adverse events associated with multiple myeloma (MM) treatments can be prevented or identified and managed at an early stage. To optimize the management of patients with multiple myeloma and cardiac comorbidities, it is important for clinicians to learn how to recognize these risks and implement appropriate management strategies.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages